Stocktoria
Aurinia Pharmaceuticals Inc. AUPH
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2001-07-16
Chart by TradingView
5/9
Piotroski F — financial health
5.18
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $283.1M | $235.1M | $175.5M | $134.0M | $45.6M |
| Operating income | $104.9M | -$4.7M | -$91.7M | -$111.5M | -$180.7M |
| Net income | $287.2M | $5.8M | -$78.0M | -$108.2M | -$181.0M |
| Operating cash flow | $135.7M | $44.4M | -$33.5M | -$79.5M | -$157.7M |
| Total assets | $751.6M | $550.6M | $548.1M | $470.9M | $543.4M |
| Total liabilities | $170.3M | $173.2M | $170.1M | $65.4M | $64.3M |
| Shareholders' equity | $581.3M | $377.5M | $378.0M | $405.4M | $479.1M |
| Ratios | |||||
| Operating margin | 37.1% | -2.0% | -52.2% | -83.2% | -396.3% |
| Net margin | 101.5% | 2.4% | -44.5% | -80.7% | -396.8% |
| Return on assets | 38.2% | 1.0% | -14.2% | -23.0% | -33.3% |
| Return on equity | 49.4% | 1.5% | -20.6% | -26.7% | -37.8% |
| Current ratio | 5.25 | 4.57 | 5.50 | 9.60 | 12.63 |
| Revenue growth | 20.4% | 34.0% | 31.0% | 193.9% | -9.0% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 1,663,835 | $24.7M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 5.18 (safe)
- Working capital / assets 0.53
- Retained earnings / assets -0.864
- EBIT / assets 0.14
- Equity / liabilities 3.414
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001600620 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.